Through this collaboration, Indica Labs’ and Paige’s customers can expect:
"We are excited to work with Indica Labs to make Paige’s powerful AI capabilities available to customers through the HALO AP platform”, said Peter Hamilton, GM of Diagnostics at Paige. “We are confident that integrating the technologies that Indica and Paige have developed will provide pathologists with the richest set of capabilities that will drive improvements in cancer diagnostics.”
Steven Hashagen, CEO of Indica Labs said, "This partnership represents a significant step forward in our commitment to delivering innovative solutions that meet the evolving needs of our customers. Paige has been a pioneer in AI for pathology diagnostics, so bringing their tools onto our platform is an exciting opportunity for us and our customers."
The joint efforts will initially focus on developing integrated solutions catering to clinical diagnostics. Integration roll-out is expected within the next few months, and collaboration efforts for the life science segment are to ensue in parallel.
About Indica Labs
Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organizations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery.
For more information, please visit https://indicalab.com or contact info@indicalab.com.
About Paige
Paige is pushing the boundaries of AI to solve cancer’s most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data from Memorial Sloan Kettering Cancer Center, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-approved AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit www.paige.ai.